Research programme: acute inflammatory disease therapy - Tanox

Drug Profile

Research programme: acute inflammatory disease therapy - Tanox

Alternative Names: Acute inflammatory disease therapy research programme - Tanox; TNX 558

Latest Information Update: 10 Aug 2007

Price : $50

At a glance

  • Originator Tanox
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 03 Aug 2007 Tanox has been acquired by Genentech
  • 04 May 2007 Preclinical development is ongoing
  • 31 Oct 2004 Preclinical trials in Inflammation in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top